Australian Institute of Health Innovation, Macquarie University, NSW North Ryde, Australia.
Laboratory Haematology and Transfusion Central Coast, NSW Health Pathology, Gosford, Australia.
Blood Transfus. 2022 Jan;20(1):50-58. doi: 10.2450/2020.0174-20. Epub 2020 Dec 1.
The appropriateness of the use of blood transfusion in patients with acute coronary syndromes (ACS) remains contested. In general, studies addressing this issue were based on data from clinical trials, registries, or electronic medical records, and were conducted across different settings. Our study aimed to use a linked patient blood management data system from existing hospital databases to examine the association between blood transfusion and in-hospital mortality, length of stay (LOS) and readmission rates among patients with ACS, and to investigate this relationship at different haemoglobin (Hb) concentrations.
This was a retrospective observational study of patients admitted to participating hospitals between 1 January 2014 to 31 December 2017 with ACS recorded as primary diagnosis. Admission and nadir Hb concentrations were categorised as ≤100 g/L and >100 g/L. Generalised estimating equations were used to investigate the association between transfusion and clinical outcomes, while accounting for the correlation of multiple admissions from the same patients across hospitals over the study period.
Of the 9,952 admissions included, blood transfusions occurred in 705 (7.1%). In unadjusted analyses, transfusion was associated with an increased risk of in-hospital mortality (OR: 2.97; 95% CI: 2.14-4.13) and an average LOS 3.55 (95% CI: 3.38-3.72) times longer. After adjusting for demographic and clinical factors, transfusion was associated with an increased risk of in-hospital mortality when Hb >100 g/L. Transfusion was not associated with the risk of readmission.
The effect of transfusion on in-hospital mortality was largely dependent on the pre-transfusion Hb concentration. When Hb was >100 g/L transfusion was associated with increased mortality, whereas when Hb ≤100 g/L no association was observed.
急性冠状动脉综合征(ACS)患者输血的适宜性仍存在争议。一般来说,针对这一问题的研究基于临床试验、登记处或电子病历数据,并在不同的环境中进行。我们的研究旨在利用现有的医院数据库中的患者血液管理数据系统,来检查输血与 ACS 患者住院死亡率、住院时间(LOS)和再入院率之间的关系,并在不同的血红蛋白(Hb)浓度下研究这种关系。
这是一项回顾性观察性研究,纳入了 2014 年 1 月 1 日至 2017 年 12 月 31 日期间因 ACS 被记录为主要诊断而入住参与医院的患者。入院时和最低 Hb 浓度被分为≤100g/L 和>100g/L。使用广义估计方程来研究输血与临床结局之间的关系,同时考虑了研究期间来自同一患者在不同医院的多次入院的相关性。
共纳入 9952 例入院患者,其中 705 例(7.1%)接受了输血。在未调整的分析中,输血与住院死亡率增加相关(OR:2.97;95%CI:2.14-4.13),且 LOS 平均延长 3.55 倍(95%CI:3.38-3.72)。在调整了人口统计学和临床因素后,当 Hb>100g/L 时,输血与住院死亡率增加相关。输血与再入院风险无关。
输血对住院死亡率的影响在很大程度上取决于输血前的 Hb 浓度。当 Hb>100g/L 时,输血与死亡率增加相关,而当 Hb≤100g/L 时,两者无相关性。